As the European markets navigate concerns about global growth and currency fluctuations, the pan-European STOXX Europe 600 Index recently ended slightly lower. Despite these challenges, certain smaller or newer companies continue to capture investor interest through their potential for growth at lower price points. While the term "penny stocks" may seem outdated, it still signifies opportunities in lesser-known companies that possess strong financials and promising prospects.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €4.188 | €1.45B | ✅ 5 ⚠️ 2 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €241.45M | ✅ 2 ⚠️ 2 View Analysis > |
| IMS (WSE:IMS) | PLN3.07 | PLN107.74M | ✅ 4 ⚠️ 2 View Analysis > |
| Siili Solutions Oyj (HLSE:SIILI) | €5.00 | €40.54M | ✅ 3 ⚠️ 3 View Analysis > |
| Euroland Société anonyme (ENXTPA:ALERO) | €3.02 | €9.58M | ✅ 2 ⚠️ 5 View Analysis > |
| ForFarmers (ENXTAM:FFARM) | €4.30 | €380.05M | ✅ 4 ⚠️ 1 View Analysis > |
| High (ENXTPA:HCO) | €3.78 | €74.3M | ✅ 2 ⚠️ 3 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.085 | €288.19M | ✅ 4 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.926 | €31.23M | ✅ 4 ⚠️ 2 View Analysis > |
Click here to see the full list of 331 stocks from our European Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Fountain (ENXTBR:FOU)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Fountain S.A. operates in the sale, rental, and servicing of machines for cold and hot drinks made from freeze-dried or grain products across France, Belgium, the Netherlands, and other European countries with a market cap of €10.34 million.
Operations: The company's revenue segment is the Corporate Beverage Market, generating €29.96 million.
Market Cap: €10.34M
Fountain S.A. demonstrates promising aspects for a penny stock with its recent financial performance. The company's net profit margin improved to 5.5% from last year's 3.7%, and earnings grew by 52.8% over the past year, surpassing industry averages. Despite high debt levels, Fountain has reduced its debt-to-equity ratio significantly over five years and maintains well-covered interest payments and operating cash flow relative to debt obligations. However, challenges remain with short-term liabilities exceeding assets and high share price volatility in recent months, which investors should consider when evaluating potential risks and rewards associated with this stock.
- Dive into the specifics of Fountain here with our thorough balance sheet health report.
- Review our historical performance report to gain insights into Fountain's track record.
Biohit Oyj (HLSE:BIOBV)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Biohit Oyj is a biotechnology company that produces and markets acetaldehyde-binding products, diagnostic tools, and systems for research institutions, healthcare, and industry globally, with a market cap of €42.66 million.
Operations: Biohit Oyj generates revenue primarily from its Diagnostic Kits and Equipment segment, which accounts for €14.28 million.
Market Cap: €42.66M
Biohit Oyj presents a mixed profile for penny stock investors. The company has shown robust earnings growth of 37.4% over the past year, surpassing industry averages, and maintains a strong net profit margin of 15.9%. It operates debt-free with short-term assets exceeding both its short- and long-term liabilities, providing financial stability. However, its return on equity is considered low at 17.3%, and earnings growth has decelerated compared to its five-year average. Recent guidance suggests steady revenue growth between €15.7 million to €17.1 million in 2025, which may appeal to those seeking potential upside in this sector.
- Click to explore a detailed breakdown of our findings in Biohit Oyj's financial health report.
- Examine Biohit Oyj's earnings growth report to understand how analysts expect it to perform.
Bredband2 i Skandinavien (OM:BRE2)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Bredband2 i Skandinavien AB (publ) offers data communication and security solutions to individuals and companies in Sweden, with a market cap of SEK3.12 billion.
Operations: The company generates revenue primarily from its National Broadband Service, amounting to SEK1.81 billion.
Market Cap: SEK3.12B
Bredband2 i Skandinavien AB offers a compelling yet cautious opportunity for penny stock investors. The company has demonstrated consistent revenue growth, with recent quarterly sales reaching SEK 469.67 million, up from SEK 429.55 million the previous year. Its operating cash flow covers debt significantly, and it maintains more cash than total debt, highlighting financial prudence. However, its return on equity is low at 19.7%, and short-term liabilities exceed assets by a wide margin (SEK248.5M vs SEK614.1M). The potential acquisition by Telia Company AB at a premium price could provide immediate value realization for shareholders if completed successfully by October 2025.
- Unlock comprehensive insights into our analysis of Bredband2 i Skandinavien stock in this financial health report.
- Assess Bredband2 i Skandinavien's future earnings estimates with our detailed growth reports.
Turning Ideas Into Actions
- Unlock our comprehensive list of 331 European Penny Stocks by clicking here.
- Ready To Venture Into Other Investment Styles? The end of cancer? These 29 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Biohit Oyj might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com